Skip to content
Loading company
Loading

Latest annual · FY2025

Millions
Total revenues
14
Gross profit
11
Operating income
(84)
Net income
(80)
Free cash flow
(64)
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2022 to FY2025
n/m
Revenue, 5 yearsFY2020 to FY2025
n/m
Net income, 5 yearsFY2020 to FY2025
n/m

Pyxis Oncology, Inc. (PYXS) financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2025FY2024ChangeSource
Revenue$13.9 million$16.1 million-14.2%10-K 2026-03-23 · proof
Gross profit$11.5 million$15.7 million-26.8%10-K 2026-03-23 · proof
Operating income-$84.4 million-$89.5 million10-K 2026-03-23 · proof
Net income-$79.6 million-$77.3 million10-K 2026-03-23 · proof
Cash from operating activities-$63.5 million-$57.7 million10-K 2026-03-23 · proof
Free cash flow-$63.5 million-$57.9 million10-K 2026-03-23 · proof
Total assets$91.5 million$157.2 million-41.8%10-K 2026-03-23 · proof
Total liabilities$38.1 million$36.4 million+4.6%10-K 2026-03-23 · proof
Cash and cash equivalents$15.4 million$19.5 million-20.8%10-K 2026-03-23 · proof
What was Pyxis Oncology, Inc. (PYXS)'s revenue in fiscal 2025?
Pyxis Oncology, Inc. (PYXS) reported revenue of $13.9 million for fiscal 2025 (the year ended Dec 31, 2025), against $16.1 million the year before (-14.2%). Source: the 10-K filed with the SEC on Mar 23, 2026. SEC
What was Pyxis Oncology, Inc. (PYXS)'s gross profit in fiscal 2025?
Pyxis Oncology, Inc. (PYXS) reported gross profit of $11.5 million for fiscal 2025 (the year ended Dec 31, 2025), against $15.7 million the year before (-26.8%). Source: the 10-K filed with the SEC on Mar 23, 2026. SEC
What was Pyxis Oncology, Inc. (PYXS)'s operating income in fiscal 2025?
Pyxis Oncology, Inc. (PYXS) reported operating income of -$84.4 million for fiscal 2025 (the year ended Dec 31, 2025), against -$89.5 million the year before. Source: the 10-K filed with the SEC on Mar 23, 2026. SEC
What was Pyxis Oncology, Inc. (PYXS)'s net income in fiscal 2025?
Pyxis Oncology, Inc. (PYXS) reported net income of -$79.6 million for fiscal 2025 (the year ended Dec 31, 2025), against -$77.3 million the year before. Source: the 10-K filed with the SEC on Mar 23, 2026. SEC
What was Pyxis Oncology, Inc. (PYXS)'s cash from operating activities in fiscal 2025?
Pyxis Oncology, Inc. (PYXS) reported cash from operating activities of -$63.5 million for fiscal 2025 (the year ended Dec 31, 2025), against -$57.7 million the year before. Source: the 10-K filed with the SEC on Mar 23, 2026. SEC
What was Pyxis Oncology, Inc. (PYXS)'s free cash flow in fiscal 2025?
Pyxis Oncology, Inc. (PYXS) reported free cash flow of -$63.5 million for fiscal 2025 (the year ended Dec 31, 2025), against -$57.9 million the year before. Source: the 10-K filed with the SEC on Mar 23, 2026. SEC
What are Pyxis Oncology, Inc. (PYXS)'s total assets?
As of Dec 31, 2025, Pyxis Oncology, Inc. (PYXS) reported total assets of $91.5 million, against $157.2 million a year earlier (-41.8%). Source: the 10-K filed with the SEC on Mar 23, 2026. SEC
What are Pyxis Oncology, Inc. (PYXS)'s total liabilities?
As of Dec 31, 2025, Pyxis Oncology, Inc. (PYXS) reported total liabilities of $38.1 million, against $36.4 million a year earlier (+4.6%). Source: the 10-K filed with the SEC on Mar 23, 2026. SEC
What are Pyxis Oncology, Inc. (PYXS)'s cash and cash equivalents?
As of Dec 31, 2025, Pyxis Oncology, Inc. (PYXS) reported cash and cash equivalents of $15.4 million, against $19.5 million a year earlier (-20.8%). Source: the 10-K filed with the SEC on Mar 23, 2026. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:PYXS&period_type=annual&limit=5"

Information only, not investment advice.